Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102928 | 0.81 | TSHR (0.42) | TSHRKDM4EAOC3 | |
| Ammonia Solution, Strong SCHEMBL4465336 | 0.80 | TSHR (0.41) | TSHRKDM4EAOC3 | |
| SCHEMBL66519 | 0.79 | MEN1 (0.49) | TAAR1KDM4EIDO1 | |
| SCHEMBL25840770 | 0.75 | TSHR (0.65) | TSHRRECQLPYCR1TAAR1KDM4E | |
| SCHEMBL11530544 | 0.72 | TSHR (0.62) | TSHRRECQLPYCR1TAAR1KDM4E | |
| SCHEMBL6982347 | 0.72 | PYCR1 (0.42) | TSHRPYCR1TAAR1KDM4EIDO1 | |
| SCHEMBL1796186 | 0.72 | APLNR (0.44) | PYCR1TAAR1KDM4EIDO1AGXT | |
| SCHEMBL6771923 | 0.70 | AOC3 (0.45) | TAAR1AOC3 | |
| SCHEMBL14673301 | 0.69 | CNR2 (0.44) | TSHRKDM4EAOC3 | |
| SCHEMBL9653111 | 0.69 | TAAR1 (0.44) | TAAR1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481517-B2 | Pyrrolidine compounds,pharmaceutical compositions containing the same, devices containing the same, and methods of treating asthma or chronic obstructive pulmonary disease by administering the same | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-07-09 | — | — | US | disclosed |
| EP-2531516-A2 | PREGNANE COMPOUNDS CONDENSED IN POSITION 16,17 WITH A PYROLIDINE RING WITH GLUCOCORTICOID ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2012-12-12 | — | — | EP | disclosed |
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| WO-2011095535-A2 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | IL5, TSLP, NR3C1 | TSHR 2750/4885RECQL 3641/4885PYCR1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.